Scinai Immunotherapeutics (SCNI) Financial Statements & Analysis

Scinai Immunotherapeutics (SCNI) Income Statement

Scinai Immunotherapeutics reported revenue of $1.31M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 99.2% from $658.00K a year earlier. Net income was $2.24M, down 53.3% year over year, a net margin of 170.7%. Gross margin was -202.3% and operating margin 170.7%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $460.00K, up 19.0% from the same quarter a year earlier.

Scinai Immunotherapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Scinai Immunotherapeutics Ltd. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2024	FY 2023	FY 2022	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Mar 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2022	Dec 2021	Mar 2021	Dec 2020	Mar 2020	Mar 2019	Dec 2017
Revenue & Gross Profit
Revenue	1.31	0.66	0.66	0.00	0.00	-	0.00	0.00	-	0.00	0.00	0.00
Cost of Revenue	3.96	1.24	1.24	0.00	0.00	-	0.75	0.71	-	0.46	0.07	0.12
Gross Profit	-2.65	-0.58	-0.58	0.00	0.00	-	-0.75	-0.71	-	0.00	0.00	0.00
Operating Expenses
Research & Development	2.37	5.53	5.53	5.21	5.77	5.77	3.25	14.42	16.01	19.88	19.27	5.58
Selling, General & Administrative	2.52	2.53	2.53	4.51	5.30	5.30	7.63	4.69	5.19	2.81	1.38	1.40
Operating Expenses	-4.89	8.06	8.06	9.71	11.06	11.06	10.86	19.11	-2.28	22.69	20.61	6.80
Operating Income	2.24	-8.64	-8.64	-9.71	-11.06	-11.06	-10.86	-19.82	2.28	-22.69	-20.61	-6.80
Other Income/Expense
Interest Income	0.02	0.10	0.10	3.92	3.05	3.05	3.15	-	0.00	0.01	1.35	0.01
Interest Expense	0.36	1.44	1.42	3.80	0.00	-	3.49	0.34	-0.35	4.28	3.78	0.02
Other Income/Expense	-0.77	13.43	14.77	3.09	5.27	2.24	-0.49	18.52	-3.85	-8.93	-2.85	-3.13
Income
Income Before Tax	-8.31	4.80	4.80	-6.50	-5.80	-5.80	-8.21	-1.30	-1.39	-31.62	-23.46	-9.93
Income Tax Expense	0.00	0.00	-	0.00	0.00	-	0.00	0.00	-	0.00	0.00	0.00
Net Income	2.24	4.80	4.80	-6.50	-5.80	-5.80	-8.21	-1.30	-1.39	-31.62	-23.46	-9.93
Net Income - Continuous Operations	-8.31	4.80	4.80	-6.50	-5.80	-5.80	-8.21	-1.30	-	-31.62	-23.46	-9.93
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-6.12	-6.99	7.87	-2.19	-5.23	-5.23	-10.39	-19.11	2.75	-22.21	-20.54	-6.67
EBIT	-7.54	-	6.22	-2.70	-	-5.80	-10.86	-	2.28	-	-	-
Depreciation & Amortization	1.42	1.65	1.65	0.51	0.56	0.56	0.18	0.71	0.47	0.46	0.07	0.12
Earnings Per Share
Basic EPS	-36.00	60.00	-	-160.00	-160000.00	-400.00	-80.00	-467560.00	-13.00	-15488000.00	-14358000.00	-7902800.00
Diluted EPS	4.00	60.00	-	-160.00	-160000.00	-400.00	-80.00	-467560.00	-13.00	-15488000.00	-14358000.00	-7902800.00
Basic Shares Outstanding	0.23	0.08	0.08	0.04	0.00	0.02	0.14	0.00	0.11	0.01	0.01	0.01
Diluted Shares Outstanding	0.23	0.08	0.08	0.04	0.00	0.02	0.14	0.00	0.11	0.01	0.01	0.01

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Scinai Immunotherapeutics Financial Statements

What was Scinai Immunotherapeutics's revenue in fiscal 2025?

Scinai Immunotherapeutics reported revenue of $1.31M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 99.2% from $658.00K a year earlier.

Is Scinai Immunotherapeutics profitable?

Yes. Scinai Immunotherapeutics earned net income of $2.24M in fiscal 2025, a net margin of 170.7%. In fiscal 2024 it earned $4.80M.

What is Scinai Immunotherapeutics's operating margin?

Scinai Immunotherapeutics's operating income was $2.24M on revenue of $1.31M in fiscal 2025, an operating margin of 170.7%, compared with -1312.8% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition